These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36548367)

  • 1. Aptamer proteomics of serum exosomes from patients with Primary Raynaud's and patients with Raynaud's at risk of evolving into Systemic Sclerosis.
    Piera-Velazquez S; Dillon ST; Gu X; Libermann TA; Jimenez SA
    PLoS One; 2022; 17(12):e0279461. PubMed ID: 36548367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of serum exosome miRNA from patients with Raynaud's phenomenon with positive and negative serum antinuclear antibodies.
    Piera-Velazquez S; Fortina P; Jimenez SA
    Clin Exp Rheumatol; 2024 Aug; 42(8):1629-1634. PubMed ID: 39152754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial.
    Watanabe A; Shima Y; Takahashi H; Akiyama Y; Kodera M; Jinnin M; Azuma N; Ishii K; Kumanogoh A
    Mod Rheumatol; 2023 Aug; 33(5):968-974. PubMed ID: 36124934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
    Bellando-Randone S; Del Galdo F; Lepri G; Minier T; Huscher D; Furst DE; Allanore Y; Distler O; Czirják L; Bruni C; Guiducci S; Avouac J; Cutolo M; Smith V; Matucci-Cerinic M;
    Lancet Rheumatol; 2021 Dec; 3(12):e834-e843. PubMed ID: 38287630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.
    Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
    Clin Rheumatol; 2022 Oct; 41(10):3049-3054. PubMed ID: 35583625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].
    Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
    Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
    Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.
    Moinzadeh P; Nihtyanova SI; Howell K; Ong VH; Denton CP
    Clin Rev Allergy Immunol; 2012 Dec; 43(3):249-55. PubMed ID: 22711501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry.
    Delisle VC; Hudson M; Baron M; Thombs BD; And The Canadian Scleroderma Research Group A
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-10-4. PubMed ID: 24144459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.
    Denton CP; Bunce TD; Dorado MB; Roberts Z; Wilson H; Howell K; Bruckdorfer KR; Black CM
    Rheumatology (Oxford); 1999 Apr; 38(4):309-15. PubMed ID: 10378706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to diagnosis in systemic sclerosis: is sex a factor?
    Hudson M; Thombs B; Baron M;
    Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raynaud's phenomenon-an update on diagnosis, classification and management.
    Pauling JD; Hughes M; Pope JE
    Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.